AUTHORS
Brian H. Johnstone, PhD, Jie Jiang, PhD2, Dongsheng Gu, PhD3, Ding-Wen Chen, PhD4, Sagar Munjal, MD, MS5, Richi Man Chugh, PhD6, Subhrajit Saha, PhD7, Erik J Woods, PhD8
AFFILIATIONS
1 Ossium Health, Inc., Indianapolis, Indiana, United States
2 Ossium Health, Inc., Indianapolis, Indiana, United States
3 Ossium Health, Inc., Indianapolis, Indiana, United States
4 Ossium Health, Inc., Indianapolis, Indiana, United States
5 Ossium Health, San Francisco, California, United States
6 University of Kansas Medical Center, Kansas City, Kansas, United States
7 University of Kansas Medical Center, Kansas City, Kansas, United States
8 Ossium Health, Inc., Indianapolis, Indiana, United States
ABSTRACT
Allogeneic hematopoietic cell transplantation (alloHCT) is a curative treatment for many bone marrow (BM) disorders; however, the current transplant system that heavily relies on living donor volunteers is beset with operational inefficiencies. Consequently, a significant number of patients requiring alloHCT are not served because donor grafts cannot be procured within the required therapeutic window. A current initiative to build a genetically diverse bank of cryopreserved whole BM recovered from consented and screened deceased organ donor (OD) vertebral bodies (VBs) addresses the need for on-demand grafts with validated functionally viable CD34+ and accessory cells. Early clinical trial data using this novel graft source for alloHCT to treat malignancies have demonstrated remarkable outcomes with highly mismatched grafts (4-6/8) and post-transplant cyclophosphamide (PTCy) GVHD prophylaxis (abstracts submitted). The present study investigated whether pathophysiological processes associated with brain death alter hematopoietic stem cell (HSC) fitness for alloHCT.
As previously demonstrated, a temporally restricted wave of IL-6 occurs with brain death. IL-6 levels in brain dead donor (BDD) VB BM inversely correlated with the interval between declaration of brain death and recovery of VBs (Spearman rs =−0.603, P=0.0049). The average concentration of IL-6 in BDD BM (N=9) was 206.5 ± 359.2 pg/mL, compared to 55.22 ± 100.8 pg/mL in plasma. The level of IL-6 in BDD BM is >100-fold greater than what has been reported in healthy donor (HD) BM (1.7 pg/ml). scRNA-seq analysis revealed an enhanced IL-6-mediated JAK/STAT3 signaling imprint on BDD BM HSCs, enhancing resilience of primitive long-term repopulating HSCs (LT-HSCs).
The transient IL-6 wave phenomenon was modeled in vitro by subjecting living healthy donor (HD) BM CD34+ cells to a brief (40 h) IL-6 stimulation at low levels (1 ng/ml), with and without soluble IL-6 receptor (sIL-6R) and then incubated for 5 days in minimal medium with SCF, TPO and FLT3L (STF). LT-HSCs lack membrane IL-6R but can signal in trans through binding of IL-6/sIL-6R complexes to the membrane gp130 protein receptor binding partner. The proportion of LT-HSCs doubled (P<0.05, ANOVA) after IL-6 stimulation in combination with sIL-6R compared to controls. Enhanced LT-HSC numbers were associated with greater viability and proliferation (CFSE dilution), resulting in 2±0.59-fold cell numbers (P<0.05, ANOVA). Pulsing with IL-6/sIL-6R also increased the clonogenic capacity of CD34+ cells without evidence of myeloid skewing as determined by colony forming unit (CFU) assays. In contrast, supraphysiological concentrations (10 and 100 ng/mL) commonly used in vitro strongly skewed towards CFU-GM (P<0.05).
We next evaluated whether an IL-6/sIL-6R pulse conferred a survival advantage upon LT-HSCs cultured under stress conditions. HD CD34+ cells were pulsed with IL-6/sIL-6R for 40 h in serum-free medium without STF cytokines. Cell numbers in the LT-HSC compartment were over 3-fold greater than control (P<0.01, ANOVA) when pulsed with IL-6/sIL-6R, which was abrogated by neutralization with sgp130Fc inhibitor. Increased survival was due to reduced cell death (27.6%) compared to the untreated controls (76.4%). Real-time PCR analysis revealed that an IL-6/sIL-6R pulse upregulated expression of stress response and growth genes such as MCL1 (1.4-fold) and JUNB (1.5-fold), conferring enhanced resilience in stress conditions. A similar enhancement of IL-6/sIL-6R pulsed LT-HSC survival was observed with an inflammatory challenge using a cocktail of factors similar to that found post-conditioning, consisting of interferon-γ, tumor necrosis factor α and interleukin1β. Importantly, stimulation of feedback regulatory mechanisms, such as SOCS1/3 (1.5 and 4.3-fold, respectively, over control), was observed which serves to limit inflammatory processes. Thus, together with PIM1 (4.8-fold increased) and BCL3 (3.1-fold increased), factors induced by a low dose IL-6/sIL-6R pulse appear to preserve LT-HSCs by preventing myeloid skewing and exhaustion, which were both observed with supraphysiological IL-6 concentrations commonly used to evaluate signaling in HSCs.
These data provide a potential mechanistic bridge between deceased donor inflammatory conditions that enhance resilience of LT-HSCs, leading to rapid engraftment and early indices of low relapse in clinical studies using BD donor BM for alloHCT (NCT05589896 and NCT07145411).
DISCLOSURES
Brian H. Johnstone, PhD: Ossium Health, Inc. - Current holder of stock options in a privately-held company; Ossium Health, Inc. - Current Employment